Awaiting product image
,

Pitavas 2

Contains: Pitavastatin Calcium equivalent to Pitavastatin 2 mg
Therapeutic Class: Lipid-Lowering Agent (Statin)
Schedule: Schedule H (Prescription Drug)

PITAVAS 2 is a statin-based lipid-lowering medication containing Pitavastatin, a potent and long-acting HMG-CoA reductase inhibitor. It is prescribed to manage hyperlipidemia and reduce cardiovascular risk by lowering LDL cholesterol, total cholesterol, and triglycerides, while modestly increasing HDL cholesterol.

Compared to other statins, Pitavastatin is minimally metabolized by the CYP450 system, making it ideal for patients on polypharmacy, especially those with diabetes, hypertension, or renal compromise.

Usage of PITAVAS 2

  • Primary hyperlipidemia and mixed dyslipidemia

  • Familial hypercholesterolemia (heterozygous)

  • Cardiovascular risk reduction in patients with multiple risk factors

  • Suitable for Type 2 diabetic dyslipidemia

  • Statin-intolerant patients who experienced muscle-related side effects with other statins

  • Can be used in moderate renal impairment without dose adjustment

Common Side Effects

  • Headache

  • Myalgia or muscle cramps

  • Constipation

  • Back pain

  • Mild increase in liver enzymes

  • Rare but serious: Rhabdomyolysis, hepatic dysfunction

Precautions

  • Liver impairment: Avoid in active liver disease; monitor liver enzymes periodically

  • Renal dysfunction: No dose adjustment in moderate impairment; use caution in severe cases

  • Alcohol abuse: May increase hepatotoxicity risk

  • Muscle symptoms: Monitor CPK levels if unexplained pain or weakness occurs

  • Pregnancy & lactation: Contraindicated – Category X

  • Use caution in elderly patients and those with hypothyroidism

Drug Interactions

  • Minimal CYP450 metabolism (mainly CYP2C9) – low interaction potential

  • Caution with:

    • Fibrates (↑ risk of myopathy)

    • Niacin (↑ risk of liver enzyme elevation and muscle effects)

    • Cyclosporine (↑ Pitavastatin levels)

    • Warfarin (monitor INR when co-administered)

  • Safer in patients taking multiple antihypertensives, antidiabetics, or immunosuppressants

Dosage and Administration

  • Once daily, preferably at night

  • Can be taken with or without food

  • Starting dose: 2 mg daily, titratable up to 4 mg based on lipid targets and tolerance

  • Regular lipid panel monitoring recommended every 4–8 weeks during titration

Storage

  • Store in a cool, dry place below 25°C

  • Keep away from light and moisture

Patient Counselling Tips

  • Emphasize importance of long-term adherence, even after lipid levels improve

  • Advise reporting of any muscle pain, weakness, or dark-colored urine immediately

  • Avoid grapefruit juice, although interaction risk is low

  • Follow a low-fat, heart-healthy diet

  • Do not use during pregnancy or while breastfeeding

Related products

Review My Order

0

Subtotal

Taxes & shipping calculated at checkout

Checkout